基于 ICD-0-3 的恶性行为食管癌患者生存率预测列线图
Nomograms to predict survival rates for esophageal cancer patients with malignant behaviors based on ICD-0-3.
机构信息
Department of Radiation Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, 277 West Yanta Road, Xi'an, Shaanxi, 710061, PR China.
The Second Department of Thoracic Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, 277 West Yanta Road, Xi'an, Shaanxi, 710061, PR China.
出版信息
Future Oncol. 2019 Jan;15(2):121-132. doi: 10.2217/fon-2018-0493. Epub 2018 Sep 20.
AIM
We aimed to investigate the effect of current treatment based on stage and histology type, which were important factors for treating esophageal cancer.
METHODS
Log-rank test, COX and nomograms were used for survival analysis. DCA, C-index and calibration curves were used for validation.
RESULTS
A total of 3224 patients were recruited. As for cT2-T4aM0 patients, chemotherapy and radiation prolonged overall survival (OS) for esophageal squamous cell carcinoma (ESCC) and chemotherapy improved OS for esophageal adenocarcinoma (EAC). Meanwhile, neoadjuvant radiotherapy had longer OS than adjuvant radiotherapy for ESCC. As for T4b patients, radiation and chemotherapy correlated with better OS for ESCC and chemotherapy prolonged OS for EAC.
CONCLUSION
Neoadjuvant radiotherapy might be optimal for cT2-T4aM0 ESCC. Radiation was recommended for T4b ESCC while chemotherapy was recommended for T4b EAC.
目的
我们旨在研究基于分期和组织学类型的现有治疗方法的效果，这些是治疗食管癌的重要因素。
方法
采用对数秩检验、COX 和列线图进行生存分析。采用 DCA、C 指数和校准曲线进行验证。
结果
共招募了 3224 名患者。对于 cT2-T4aM0 患者，化疗和放疗延长了食管鳞癌（ESCC）的总生存期（OS），化疗改善了食管腺癌（EAC）的 OS。同时，新辅助放疗比辅助放疗对 ESCC 有更长的 OS。对于 T4b 患者，放疗和化疗与 ESCC 的更好 OS 相关，化疗延长了 EAC 的 OS。
结论
新辅助放疗可能是 cT2-T4aM0 ESCC 的最佳选择。对于 T4b ESCC 推荐放疗，而 T4b EAC 推荐化疗。
Zotero 插件